Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: Secondary outcome of the randomized phase III EORTC 26101 study.
- DOI
- 10.1093/nop/npae091
- Published
- 2025 Apr
- Container
- Neuro-oncology practice
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/nop/npae091,
title = {Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: Secondary outcome of the randomized phase III EORTC 26101 study.},
author = {Dirven L and Machingura A and van den Bent MJ and Coens C and Bottomley A and Brandes AA and Domont J and Idbaih A and Koekkoek JAF and Reijneveld JC and Platten M and Wick W and Taphoorn MJB},
year = {2025},
journal = {Neuro-oncology practice},
doi = {10.1093/nop/npae091},
url = {https://doi.org/10.1093/nop/npae091}
}RIS
TY - JOUR TI - Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: Secondary outcome of the randomized phase III EORTC 26101 study. AU - Dirven L AU - Machingura A AU - van den Bent MJ AU - Coens C AU - Bottomley A AU - Brandes AA AU - Domont J AU - Idbaih A AU - Koekkoek JAF AU - Reijneveld JC AU - Platten M AU - Wick W AU - Taphoorn MJB PY - 2025 JO - Neuro-oncology practice DO - 10.1093/nop/npae091 UR - https://doi.org/10.1093/nop/npae091 ER -
APA
L, D., A, M., MJ, V. D. B., C, C., A, B., AA, B., J, D., A, I., JAF, K., JC, R., M, P., W, W., & MJB, T. (2025). Health-related quality of life in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only: Secondary outcome of the randomized phase III EORTC 26101 study.. Neuro-oncology practice. https://doi.org/10.1093/nop/npae091
Source records
- pubmed · retrieved 2026-09-25T23:29:33.894Z